Paraoxonase 1 activities and polymorphisms in autism spectrum disorders

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 3, 2010, Pages 600-607

  Paşca, Sergiu P ^a,b   Dronca, Eleonora ^a   Nemeş, Bogdan ^a   Kaucsár, Tamás ^a   Endreffy, Emõke ^c   Iftene, Felicia ^a   Benga, Ileana ^a   Cornean, Rodica ^a   Dronca, Maria ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Center for Cognitive and Neural Studies Coneural   (Romania)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Arylesterase; Autism; Paraoxonase; Polymorphisms

Indexed keywords

ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ARTICLE; AUTISM; BLOOD; CHILD; ENZYME ASSAY; ENZYMOLOGY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM;

ARYLDIALKYLPHOSPHATASE; AUTISTIC DISORDER; CHILD; ENZYME ASSAYS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, GENETIC;

EID: 77953523719     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00414.x     Document Type: Article

References (62)

1. Diagnostic and statistical manual-text revision. 2000, American Psychiatric Association, 4th ed, Washington, DC, American Psychiatric Association
2. Herbert MR, Russo JP, Yang S. Autism and environmental genomics. Neurotoxicology. 2006, 27:671-84.
3. Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 2006, 29:349-58.
4. Schanen NC. Epigenetics of autism spectrum disorders. Hum Mol Genet 2006, 15:R138-50.
5. Young JG, Eskenazi B, Gladstone EA. Association between in utero organophosphate pesticide exposure and abnormal reflexes in neonates. Neurotoxicology. 2005, 26:199-209.
6. Engel SM, Berkowitz GS, Barr DB. Prenatal organophosphate metabolite and organochlorine levels and performance on the Brazelton Neonatal Behavioral Assessment Scale in a multiethnic pregnancy cohort. Am J Epidemiol. 2007, 165:1397-404.
7. Worth J. Paraoxonase polymorphisms and organophosphates. Lancet. 2002, 360:802-3.
8. Eskenazi B, Marks AR, Bradman A. Organophosphate pesticide exposure and neurodevelopment in young Mexican-American children. Environ Health Perspect. 2007, 115:792-8.
9. Costa LG, Vitalone A, Cole TB. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005, 69:541-50.
10. Aviram M, Rosenblat M, Bisgaier CL. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998, 101:1581-90.
11. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs. 2004, 4:211-7.
12. Billecke S, Draganov D, Counsell R. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000, 28:1335-42.
13. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem. 2000, 275:3957-62.
14. La Du BN, Aviram M, Billecke S. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999, 119-120:379-88.
15. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 1999, 9:745-53.
16. Humbert R, Adler DA, Disteche CM. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993, 3:73-6.
17. Adkins S, Gan KN, Mody M. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993, 52:598-608.
18. Garin MC, James RW, Dussoix P. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997, 99:62-6.
19. Davies HG, Richter RJ, Keifer M. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996, 14:334-6.
20. Chen J, Kumar M, Chan W. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect. 2003, 111:1403-9.
21. Blatter MC, James RW, Messmer S. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 1993, 211:871-9.
22. Mackness B, Mackness MI, Arrol S. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998, 423:57-60.
23. Brophy VH, Jampsa RL, Clendenning JB. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet. 2001, 68:1428-36.
24. Jarvik GP, Rozek LS, Brophy VH. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol. 2000, 20:2441-7.
25. Brophy VH, Jarvik GP, Richter RJ. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics. 2000, 10:453-60.
26. D'Amelio M, Ricci I, Sacco R. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. Mol Psychiatry. 2005, 10:1006-16.
27. Paşca SP, Nemes B, Vlase L. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci. 2006, 78:2244-8.
28. Eckerson HW, Romson J, Wyte C. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 1983, 35:214-27.
29. Pocsai Z, Toth Z, Paragh G. Rapid genotyping of paraoxonase 55 and 192 mutations by melting point analysis using real time PCR technology. Clin Chim Acta. 2003, 332:31-6.
30. Lewontin RC. On measures of gametic disequilibrium. Genetics 1988, 120:849-52.
31. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983, 35:1126-38.
32. Serajee FJ, Nabi R, Zhong H. Polymorphisms in xenobiotic metabolism genes and autism. J Child Neurol. 2004, 19:413-7.
33. Wheeler JG, Keavney BD, Watkins H. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 2004, 363:689-95.
34. Arca M, Ombres D, Montali A. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest. 2002, 32:9-15.
35. Deakin S, Leviev I, Nicaud V. Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. J Clin Endocrinol Metab. 2002, 87:1268-73.
36. Gardemann A, Philipp M, Hess K. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis. 2000, 152:421-31.
37. Catano HC, Cueva JL, Cardenas AM. Distribution of paraoxonase-1 gene polymorphisms and enzyme activity in a Peruvian population. Environ Mol Mutagen. 2006, 47:699-706.
38. Roest M, van Himbergen TM, Barendrecht AB. Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest. 2007, 37:187-96.
39. Berkowitz GS, Wetmur JG, Birman-Deych E. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ Health Perspect. 2004, 112:388-91.
40. Whyatt RM, Rauh V, Barr DB. Prenatal insecticide exposures and birth weight and length among an urban minority cohort. Environ Health Perspect. 2004, 112:1125-32.
41. Betancourt AM, Burgess SC, Carr RL. Effect of developmental exposure to chlorpyrifos on the expression of neurotrophin growth factors and cell-specific markers in neonatal rat brain. Toxicol Sci. 2006, 92:500-6.
42. Cole TB, Jampsa RL, Walter BJ. Expression of human paraoxonase (PON1) during development. Pharmacogenetics. 2003, 13:357-64.
43. Costa LG, McDonald BE, Murphy SD. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol. 1990, 103:66-76.
44. Keller F, Persico AM. The neurobiological context of autism. Mol Neurobiol. 2003, 28:1-22.
45. Aviram M, Hardak E, Vaya J. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000, 101:2510-7.
46. Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med. 2003, 81:766-79.
47. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. 2006, 13:171-81.
48. Deth R, Muratore C, Benzecry J. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. Neurotoxicology. 2008, 29:190-201.
49. Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev. 2006, 9:485-99.
50. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002, 46:76-84.
51. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol. 2001, 120:170-9.
52. Leduc V, Poirier J. Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener Dis. 2008, 5:225-7.
53. Benmoyal-Segal L, Vander T, Shifman S. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. FASEB J. 2005, 19:452-4.
54. Perry EK, Lee ML, Martin-Ruiz CM. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry. 2001, 158:1058-66.
55. Nguyen SD, Sok DE. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radic Res. 2003, 37:1319-30.
56. Hernandez A, Gomez MA, Pena G. Effect of long-term exposure to pesticides on plasma esterases from plastic greenhouse workers. J Toxicol Environ Health A. 2004, 67:1095-108.
57. Rozenberg O, Aviram M. S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun. 2006, 351:492-8.
58. Horvath K, Perman JA. Autistic disorder and gastrointestinal disease. Curr Opin Pediatr. 2002, 14:583-7.
59. Schulpis KH, Barzeliotou A, Papadakis M. Maternal chronic hepatitis B virus is implicated with low neonatal paraoxonase/arylesterase activities. Clin Biochem. 2008, 41:282-7.
60. Okita C, Meguro M, Hoshiya H. A new imprinted cluster on the human chromosome 7q21-q31, identified by human-mouse monochromosomal hybrids. Genomics. 2003, 81:556-9.
61. Badcock C, Crespi B. Imbalanced genomic imprinting in brain development: an evolutionary basis for the aetiology of autism. J Evol Biol. 2006, 19:1007-32.
62. Ronald A, Happe F, Bolton P. Genetic heterogeneity between the three components of the autism spectrum: a twin study. J Am Acad Child Adolesc Psychiatry. 2006, 45:691-9.